New drug offers hope for those with lung cancer
Clinicians can now offer their patients the first targeted oral therapy to be approved for the treatment of non-small cell lung cancer (NSCLC). The FDA recently approved gefitinib (Iressa, AstraZeneca) as monotherapy for the treatment of patients with locally advanced or metastatic NSCLC after failure of both platinum-based and docetaxel chemotherapies. Gefitinib was reviewed and approved under the Agency?s accelerated approval program. The drug is currently available in pharmacies.
Newsletter
Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.
Related Content
